Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

Trial to evaluate Trevena's TRV-734 for opioid use disorder

Dec. 24, 2019

Embera NeuroTherapeutics receives funding to advance EMB-001 into phase II studies

Dec. 20, 2019

Indivior selects CRO to conduct phase I study of INDV-2000

Dec. 10, 2019

Adamis Pharmaceuticals receives a complete response letter regarding Zimhi

Nov. 26, 2019

Binging brains give themselves away

Nov. 26, 2019

Diabetes drug eases nicotine withdrawal

Nov. 14, 2019

New phase II trial studies suvorexant for comorbid sleep disorder and alcohol dependence

Oct. 24, 2019

Dosing begins in NIH-funded phase II proof-of-concept study of ANS-6637

Oct. 18, 2019

AstraZeneca initiates first-in-human study of AZD-4041 in healthy volunteers

Oct. 15, 2019

Humanetics' development of radioprotectant BIO-301 supported by DoD cooperative research agreement

Oct. 2, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
Medline raises $6.3B in fourth med-tech IPO of December
BioWorld MedTech
Medline Inc. returned to the public markets with a blockbuster IPO of $6.26 billion, reportedly this year’s largest IPO globally. The upsized offering of more...
Vitesse finesse pays off: DBV wins in peanut allergy phase III
BioWorld
DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and officials plan a BLA filing with the U.S....
Acryl raises $28M IPO, aiming to bridge medical divide with AI
BioWorld MedTech
Acryl Inc. debuted on South Korea’s Kosdaq Dec. 16, raising ₩42.12 billion ($28.5 million) in an IPO. Shares (KOSDAQ:0007C0) closed at ₩67,000 on the first day,...